RhAPPcast
FAQ: What is the MOA of guselkumab and icotrokinra?
1:36
In this FAQ video module, Jennifer Mylod, a rheumatology nurse practitioner in Phoenix, Arizona, compares the mechanisms of action of guselkumab and icotrokinra within the interleukin-23 (IL-23)/T-helper 17 (Th17) signaling pathway. This overview highlights the differences between an injectable monoclonal antibody that targets the IL-23 cytokine and an oral peptide that selectively binds the…